PortfoliosLab logoPortfoliosLab logo
DBVT vs. TRVI
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

DBVT vs. TRVI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in DBV Technologies S.A. (DBVT) and Trevi Therapeutics, Inc. (TRVI). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, DBVT achieves a -7.67% return, which is significantly lower than TRVI's 7.43% return.


DBVT

1D
-2.91%
1M
-9.09%
YTD
-7.67%
6M
36.26%
1Y
122.92%
3Y*
-3.83%
5Y*
-20.40%
10Y*
-25.38%

TRVI

1D
-0.37%
1M
-6.47%
YTD
7.43%
6M
-1.82%
1Y
126.05%
3Y*
81.76%
5Y*
44.88%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

DBVT vs. TRVI - Yearly Performance Comparison


2026 (YTD)2025202420232022202120202019
DBVT
DBV Technologies S.A.
-7.67%520.39%-67.57%-37.73%-4.37%-38.93%-75.51%12.51%
TRVI
Trevi Therapeutics, Inc.
7.43%203.88%207.46%-30.57%146.74%-67.68%-35.47%-52.47%

Correlation

The correlation between DBVT and TRVI is 0.20, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.20

Correlation (3Y)
Calculated over the trailing 3-year period

0.08

Correlation (5Y)
Calculated over the trailing 5-year period

0.10

Correlation (All Time)
Calculated using the full available price history since May 8, 2019

0.12

The correlation between DBVT and TRVI shifts across timeframes, from 0.08 (3 years) to 0.20 (1 year), reflecting how their relationship changes across market environments.

Fundamentals

EPS

DBVT:

-$1.89

TRVI:

-$0.43

Total Revenue (TTM)

DBVT:

$0.00

TRVI:

$0.00

Gross Profit (TTM)

DBVT:

-$8.90M

TRVI:

-$31.00K

EBITDA (TTM)

DBVT:

-$159.48M

TRVI:

-$49.16M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

DBVT vs. TRVI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DBVT
DBVT Risk / Return Rank: 8383
Overall Rank
DBVT Sharpe Ratio Rank: 8282
Sharpe Ratio Rank
DBVT Sortino Ratio Rank: 8383
Sortino Ratio Rank
DBVT Omega Ratio Rank: 7878
Omega Ratio Rank
DBVT Calmar Ratio Rank: 8989
Calmar Ratio Rank
DBVT Martin Ratio Rank: 8383
Martin Ratio Rank

TRVI
TRVI Risk / Return Rank: 8686
Overall Rank
TRVI Sharpe Ratio Rank: 8888
Sharpe Ratio Rank
TRVI Sortino Ratio Rank: 8484
Sortino Ratio Rank
TRVI Omega Ratio Rank: 8383
Omega Ratio Rank
TRVI Calmar Ratio Rank: 8989
Calmar Ratio Rank
TRVI Martin Ratio Rank: 8787
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DBVT vs. TRVI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for DBV Technologies S.A. (DBVT) and Trevi Therapeutics, Inc. (TRVI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


DBVTTRVIDifference
Sharpe ratioReturn per unit of total volatility

-0.49

Sortino ratioReturn per unit of downside risk

-0.04

Omega ratioGain probability vs. loss probability

1.29

1.34

-0.05

Calmar ratioReturn relative to maximum drawdown

4.44

4.30

+0.14

Martin ratioReturn relative to average drawdown

7.82

9.65

-1.83

DBVT vs. TRVI - Sharpe Ratio Comparison

The current DBVT Sharpe Ratio is 1.56, which is comparable to the TRVI Sharpe Ratio of 2.05. The chart below compares the historical Sharpe Ratios of DBVT and TRVI, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


DBVTTRVIDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.56

2.05

-0.49

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.22

0.51

-0.73

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.30

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.24

0.08

-0.32

Drawdowns

DBVT vs. TRVI - Drawdown Comparison

The maximum DBVT drawdown since its inception was -99.52%, roughly equal to the maximum TRVI drawdown of -95.45%. Use the drawdown chart below to compare losses from any high point for DBVT and TRVI.


Loading charts...

Drawdown Indicators


DBVTTRVIDifference

Max Drawdown

Largest peak-to-trough decline

-99.52%

-95.45%

-4.07%

Max Drawdown (1Y)

Largest decline over 1 year

-27.87%

-29.50%

+1.63%

Max Drawdown (3Y)

Largest decline over 3 years

-89.29%

-61.96%

-27.33%

Max Drawdown (5Y)

Largest decline over 5 years

-96.34%

-80.26%

-16.08%

Max Drawdown (10Y)

Largest decline over 10 years

-99.52%

Current Drawdown

Current decline from peak

-96.41%

-12.66%

-83.75%

Average Drawdown

Average peak-to-trough decline

-70.27%

-61.65%

-8.62%

Ulcer Index

Depth and duration of drawdowns from previous peaks

15.77%

13.11%

+2.66%

Volatility

DBVT vs. TRVI - Volatility Comparison

The current volatility for DBV Technologies S.A. (DBVT) is 9.52%, while Trevi Therapeutics, Inc. (TRVI) has a volatility of 12.89%. This indicates that DBVT experiences smaller price fluctuations and is considered to be less risky than TRVI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


DBVTTRVIDifference

Volatility (1M)

Calculated over the trailing 1-month period

9.52%

12.89%

-3.37%

Volatility (6M)

Calculated over the trailing 6-month period

57.53%

39.81%

+17.72%

Volatility (1Y)

Calculated over the trailing 1-year period

79.32%

62.15%

+17.17%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

92.75%

88.27%

+4.48%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

85.49%

99.32%

-13.83%

Dividends

DBVT vs. TRVI - Dividend Comparison

Neither DBVT nor TRVI has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

DBVT vs. TRVI - Financials Comparison

This section allows you to compare key financial metrics between DBV Technologies S.A. and Trevi Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


-2.00M0.002.00M4.00M6.00M8.00M2022202320242025202600
(DBVT) Total Revenue
(TRVI) Total Revenue
Values in USD except per share items

Frequently Asked Questions


DBVT and TRVI have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

TRVI has higher volatility (12.89%) compared to DBVT (9.52%). In terms of maximum drawdown, DBVT dropped -99.52% vs TRVI's -95.45%.

TRVI currently has the higher Sharpe Ratio (2.05 vs 1.56), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for DBVT and TRVI

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer